Insulet

PODD · NASDAQ · USD

131,69 $Variation par rapport à la clôture précédente: +0,69 %Variation absolue: +0,90 $

Clôture · 2 octobre 2026

Profil de la société

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Description disponible en anglais.

Informations sur la société

Secteur
Santé
Industrie
Medical Devices
Siège
100 Nagog Park, 01720, Acton
Salariés
5 400
Cotation
PODD · NASDAQ
Indices
S&P 500
Devise
USD
ISIN
US45784P1012
Site web
insulet.com